If you look at my chart on SPPI you can se it dosent look very well. We need to have good CUP data anytime soon. The support level is far away and the resitance is on the two green lines. But can we break the two green lines, the sky’s the limit.
Nordic Blog, Debate & Chat Community for international and local investors seeking investment opportunities in Healthcare, Biotech, Medico & Pharma stocks
Set your Twitter account name in your settings to use the TwitterBar Section.
Pages
The Latest
-
Når kunstig intelligens møder medicin: Hvilke børsnoterede medicinalselskaber satser mest på AI?
Kunstig intelligens er ved at ændre spillereglerne i medicinalindustrien. Hvor udvikling af […]
More
Founded by:
Recommended reading:
Thankyou for your answer, I belive that it is in us $…and I know that it never goes as you wish in biotech….
This is a tuff question. It depends on Apaziquone and Belinostat data. I can talk about what i expect if everything go straight trough. But as you know, it never does this in biotech.
If Apaziquone and Belinostat are good and approved in 2013, and Zevalin sales rises with Fusilev. I can se 50 in 2013, 100 in 2014 and maybe 200 in 2015. If Belinostat in CUP get approved after this phase II or gets significant off label sales it can be better. but again, its blueskye
Good work, what is your target in 1,2 and 3 years.